Coherus BioSciences, Inc. financial data

Symbol
CHRS on Nasdaq
Location
C/O Dennis M. Lanfear, 333 Twin Dolphin Dr, Suite 600, Redwood City, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 7, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 128 % -4.62%
Quick Ratio 5.46 % -66.1%
Debt-to-equity -722 % -13.2%
Return On Assets 40.8 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 116M shares +0.88%
Common Stock, Shares, Outstanding 116M shares +0.89%
Entity Public Float 171M USD -47.4%
Common Stock, Value, Issued 12K USD 0%
Weighted Average Number of Shares Outstanding, Basic 116M shares +1.1%
Weighted Average Number of Shares Outstanding, Diluted 116M shares +1.1%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 95M USD -6%
Costs and Expenses 367M USD -5.07%
Operating Income (Loss) -95.2M USD +54.3%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 59.1M USD +18.2%
Income Tax Expense (Benefit) -380K USD
Net Income (Loss) Attributable to Parent 180M USD
Earnings Per Share, Basic 1 USD/shares
Earnings Per Share, Diluted 1 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 217M USD +36.2%
Marketable Securities, Current 20.7M USD
Inventory, Net 4.51M USD -92.7%
Assets, Current 380M USD -31.9%
Property, Plant and Equipment, Net 1.91M USD -42.8%
Operating Lease, Right-of-Use Asset 4.52M USD -23.6%
Intangible Assets, Net (Excluding Goodwill) 71.7M USD +1108%
Goodwill 943K USD 0%
Other Assets, Noncurrent 5.04M USD -39%
Assets 439M USD -34.9%
Accounts Payable, Current 37.6M USD -51%
Employee-related Liabilities, Current 11M USD -22.2%
Accrued Liabilities, Current 14.2M USD -76.8%
Liabilities, Current 264M USD -43.1%
Deferred Income Tax Liabilities, Net 1.1M USD 0%
Operating Lease, Liability, Noncurrent 3.29M USD -34%
Other Liabilities, Noncurrent 16.7M USD -39.6%
Liabilities 320M USD -57.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax -275K USD -1.1%
Retained Earnings (Accumulated Deficit) -1.31B USD +12.1%
Stockholders' Equity Attributable to Parent 120M USD
Liabilities and Equity 439M USD -34.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -25.8M USD +44.8%
Net Cash Provided by (Used in) Financing Activities -264K USD -130%
Net Cash Provided by (Used in) Investing Activities -17.5M USD -109%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 116M shares +0.89%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -43.6M USD -128%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 217M USD +36%
Deferred Tax Assets, Valuation Allowance 413M USD -2.49%
Deferred Tax Assets, Gross 419M USD -2.57%
Operating Lease, Liability 4.98M USD -22.2%
Payments to Acquire Property, Plant, and Equipment 152K USD -75.3%
Lessee, Operating Lease, Liability, to be Paid 5.85M USD -26.4%
Operating Lease, Liability, Current 1.69M USD +18.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.13M USD -3.01%
Lessee, Operating Lease, Liability, to be Paid, Year One 2.19M USD +4.63%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 871K USD -43.6%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.53M USD -28%
Deferred Tax Assets, Operating Loss Carryforwards 158M USD -7.23%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 19.2M USD +10.5%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.53M USD +424%
Additional Paid in Capital 1.43B USD +1.72%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 3.1M USD -14.3%
Depreciation, Depletion and Amortization 1.4M USD -46.2%
Deferred Tax Assets, Net of Valuation Allowance 6.32M USD -7.65%
Share-based Payment Arrangement, Expense 24M USD -31.9%
Interest Expense 24.4M USD -13%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%